IMGN Financial Facts
Research and development support: 2.26MTotal operating expenses: 26.31M
See Full Income Statement
Additional paid-in capital: 693.05M
Total liabilities: 89.68M
See Full Balance Sheet
Earnings History for Immunogen Inc. (IMGN)
|
Expand Research on IMGN
| Next EPS Date | 8/2/13 *Est. | EPS Growth Rate | +91.7% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +13.5% | Revenue Growth Rate | +669.2% *Last Qtr. |
| Average % Move 1-Wk after EPS | -10.0% |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Estimize EPS/Revs | Gd. | % Since | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
4/26/13  |
 |
Q313 | -$0.02 | -$0.15 | +$0.13 | $25M | $11.94M | N/A / N/A | N/A | +9.1% | Details |
| 1/25/13 | Q213 | -$0.29 | -$0.25 | -$0.04 | $2.6M | $6.02M | N/A / N/A | N/A | +6.7% | Details | |
| 10/26/12 |
Q113 | -$0.30 | -$0.25 | -$0.05 | $4.1M | $4.1M | N/A / N/A | N/A | +18.9% | Details | |
| 8/3/12 |
|
Q412 | -$0.29 | -$0.30 | +$0.01 | $2.95M | $3.26M | N/A / N/A | N/A | +6.3% | Details |
| 4/27/12 |
|
Q312 | -$0.24 | -$0.25 | +$0.01 | $3.25M | $4.24M | N/A / N/A | N/A | +29.2% | Details |
| 1/27/12 |
|
Q212 | -$0.17 | -$0.23 | +$0.06 | $7.6M | $5.43M | N/A / N/A | N/A | +30.3% | Details |
| 10/27/11 |
|
Q112 | -$0.26 | -$0.22 | -$0.04 | $2.5M | $5.61M | N/A / N/A | N/A | +13.4% | Details |
| 8/3/11 |
Q411 | -$0.23 | -$0.24 | +$0.01 | N/A | $4.41M | N/A / N/A | N/A | +32.8% | Details |
